Wall Street analysts expect Iterum Therapeutics PLC (NASDAQ:ITRM) to announce earnings of ($1.47) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Iterum Therapeutics’ earnings. The business is expected to announce its next earnings report on Monday, June 24th.
According to Zacks, analysts expect that Iterum Therapeutics will report full year earnings of ($5.85) per share for the current fiscal year. For the next fiscal year, analysts expect that the firm will post earnings of ($1.90) per share. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Iterum Therapeutics.
Several equities research analysts have issued reports on ITRM shares. Zacks Investment Research downgraded Iterum Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 6th. ValuEngine downgraded Iterum Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 25th. Finally, Needham & Company LLC restated a “buy” rating and issued a $20.00 price target on shares of Iterum Therapeutics in a report on Monday. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Iterum Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $18.40.
An institutional investor recently bought a new position in Iterum Therapeutics stock. Hound Partners LLC acquired a new position in shares of Iterum Therapeutics PLC (NASDAQ:ITRM) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 19,500 shares of the company’s stock, valued at approximately $129,000. Hound Partners LLC owned approximately 0.14% of Iterum Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 45.16% of the company’s stock.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Further Reading: Why do companies pay special dividends?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.